Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase NA 1Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 23Gynecologic 1Endocrine 1CNS 1

Conditions

Paraganglioma, Extra-Adrenal 1Carcinoma, Medullary 1

Interventions

Eating 5Standard of Care 4Radiofrequency Ablation 4Exercise 4Surgical Procedures, Operative 3Radiosurgery 3Endoscopic Mucosal Resection 3Adrenalectomy 3lutetium Lu 177 dotatate 2Yoga 2Saline Solution 2Robotic Surgical Procedures 2Resistance Training 2Proton Therapy 2Propofol 2Palliative Care 2Octreotide 2Magnetic Resonance Imaging 2Lutetium-177 2Liquid Biopsy 2Interviews as Topic 2Hydrocortisone 2Diet, Mediterranean 2Diet 2Desflurane 2Data Collection 2Conversion to Open Surgery 2Control Groups 2Calcium 23-Iodobenzylguanidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × lenvatinib × Endocrine × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡